top of page
BPC-157 10MG

BPC-157 10MG

$97.00Price
Excluding Sales Tax
BPC‑157 (Body Protection Compound‑157) is a research-grade, synthetic 15‑amino‑acid peptide originally identified in human gastric juice and later synthesized for laboratory studies. Unlike many endocrine-related peptides, it's primarily examined for its potential in tissue repair, inflammation modulation, and protective mechanisms across multiple organ systems.
Quantity

  • BPC-157 – Research & Chemical Profile

    Description

    BPC‑157 (also known as PL 14736, Body Protection Compound‑157, or bepecin) is a synthetic, research‑grade pentadecapeptide originally derived from studies of human gastric juice. Its 15‑amino‑acid sequence is Gly‑Glu‑Pro‑Pro‑Pro‑Gly‑Lys‑Pro‑Ala‑Asp‑Asp‑Ala‑Gly‑Leu‑Val. Preclinical models suggest cytoprotective and pro‑healing activity across gastrointestinal and musculoskeletal tissues.

     

    Chemical Structure / Identifiers

    Property

    Detail

    Sequence

    Gly‑Glu‑Pro‑Pro‑Pro‑Gly‑Lys‑Pro‑Ala‑Asp‑Asp‑Ala‑Gly‑Leu‑Val (PMC, PubChem)

    Molecular Formula

    C62H98N16O22 (PubChem)

    Molecular Weight

    ≈ 1419.55 g/mol (MDPI Pharmaceuticals 2025)

    Synonyms

    PL 14736; Body Protection Compound‑157; Bepecin (Wikipedia/PMID reviews)

    CAS Number

    137525‑51‑0 (Wikipedia)

    PubChem CID

    9941957 (PubChem)

     

    Primary Research Focus

    • Gastrointestinal mucosal protection and ulcer healing in rodent models. (PMC)
    • Tendon, ligament, and muscle healing: accelerated recovery in transected tendon and surgically injured ligament models; enhanced tendon‑cell outgrowth and survival in vitro. (PubMed)
    • Skin wound healing in hyperglycemic rats. (PubMed)
    • Broad cytoprotective and angiogenic effects discussed in narrative reviews; emerging interest in orthopaedic sports medicine. (PMC)

     

    Safety / Limitations

    • Not FDA‑approved; human clinical data remain limited. (Wikipedia; narrative reviews)
    • Some clinical experience reported in inflammatory bowel disease trials, but robust, peer‑reviewed randomized human studies are sparse. (PubMed/PMC)
    • Unregulated supply chains and variability in product quality are frequent concerns. (PMC review, 2025)
    • Research Use Only; safety and efficacy have not been established for diagnosis, treatment, or prevention of disease.

     

    Key Publications / References

    Pentadecapeptide BPC 157 enhances the growth of tendon out from tendon explants and fibroblast migration (Journal of Applied Physiology). PubMed: https://pubmed.ncbi.nlm.nih.gov/21030672/  PMC overview: https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/

    Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tenocyte growth. J Orthop Res. 2003;21(6):976‑983. PubMed: https://pubmed.ncbi.nlm.nih.gov/14554208/

    PL‑14736 (BPC‑157) accelerates deficient skin wound healing in hyperglycemic rats. J Vasc Res. 2006;43(5):386‑394. PubMed: https://pubmed.ncbi.nlm.nih.gov/16785777/

    Stable gastric pentadecapeptide BPC 157: review of anti‑ulcer and systemic cytoprotective effects. World J Gastroenterol. 2015. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC4717094/

    Stable gastric pentadecapeptide BPC 157 as a therapy in rats with quadriceps tendon dissection. Int J Mol Sci. 2021. PubMed: https://pubmed.ncbi.nlm.nih.gov/34829776/

    Emerging use of BPC‑157 in orthopaedic sports medicine (2025 review). PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/

    PubChem Compound Summary for BPC‑157. PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Bpc-157

    Pharmaceuticals 2025 review: Multifunctionality and possible medical application of BPC‑157. MDPI: https://www.mdpi.com/1424-8247/18/2/185

    Wikipedia entry for cross‑checking identifiers (CAS, synonyms). https://en.wikipedia.org/wiki/BPC-157

bottom of page